27.01.2020 • NewsElaine BurridgePiramalClarivate Analytics

Piramal Sells Healthcare Analytics to Clarivate

Piramal Sells Healthcare Analytics to Clarivate
Piramal Sells Healthcare Analytics to Clarivate

Piramal Enterprises Ltd., part of Indian conglomerate Piramal Group, has agreed to sell its healthcare insights and analytics business Decision Resources Group (DRG) to Clarivate Analytics for $950 million.

The sale remains subject to shareholder approval but is expected to close by the end of February 2020.

 “We are pleased to have grown DRG’s market leadership over the last few years and believe that through this combination, Clarivate, with its size and scale, is well positioned to further accelerate DRG’s growth potential,” said Piramal Group chairman Ajay Piramal.

Jerre Stead, executive chairman and CEO Clarivate Analytics, said the “milestone” acquisition doubles the size of its Life Science business and he expects DRG to increase Clarivate’s total revenue by 20% and deliver around $77 million in annual adjusted EBITDA before the pursuit of any revenue synergies.

The US-based company added that DRG will see it well positioned in the $19 billion Life Sciences analytics market, which is enjoying double-digit growth, to support customers across the entire drug, device and medical technology lifecycle from research to outcome, helping them to improve the commercialization of life-changing therapies.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.